Health Law Update

Home | Health Law Update

<img class="alignright wp-image-3183 size-medium" src="https://healthlawupdate.bakerhostetlerblogs.com/wp-content/uploads/sites/19/2015/06/science-iStock_000002090702_Large-300x199.jpg" alt="pouring" width="300" height="199" />Efforts to extend the life cycle of pharmaceutical products frequently involve innovations and improvements in product design, formulation, route of administration and treatment indications. In addition, negotiation of agreements with competitors, including generic and biosimilar manufacturers, is frequently employed as part of a life cycle management strategy. However, recent changes in patent, regulatory, and antitrust laws have introduced greater complexity and higher risk into these strategies.

On October 23, 2015, a distinguished panel of BakerHostetler partners led an exclusive seminar in person and online at which they discussed these and related issues and provided suggestions for developing successful life cycle management strategies. Partners <a href="http://www.bakerlaw.com/CarlWHittinger">Carl Hittinger</a>, <a href="http://www.bakerlaw.com/LeeHRosebush">Lee Rosebush</a>, <a href="http://www.bakerlaw.com/LanceLShea">Lance Shea</a> and <a href="http://www.bakerlaw.com/SMauriceValla">Maurice Valla</a> are all deeply knowledgeable attorneys with decades of experience in helping clients meet their pharmaceutical business objectives.

We are delighted to share with you a brief on the seminar highlights, and hope you enjoy these insider perspectives on issues and approaches for developing successful life cycle management strategies.

<a class="js-autopdflink" href="http://bakerlaw.com/files/uploads/News/Articles/LITIGATION/FDA/Brief-Pharmaceutical-Life-Cycle-Management.pdf" target="_blank" rel="noopener">Read the brief</a>.

Pharmaceutical Life Cycle Management: Navigating the New IP, FDA, and Antitrust Terrain